These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31604095)

  • 1. Apremilast and psoriasis in the real world: A retrospective case series.
    Dozier L; Bartos G; Kerdel F
    J Am Acad Dermatol; 2020 Jul; 83(1):221-222. PubMed ID: 31604095
    [No Abstract]   [Full Text] [Related]  

  • 2. Real-World Experience With Apremilast in Treating Psoriasis.
    Mayba JN; Gooderham MJ
    J Cutan Med Surg; 2017; 21(2):145-151. PubMed ID: 27846617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world data on the efficacy and safety of apremilast in Japanese patients with plaque psoriasis.
    Ohata C; Ohyama B; Kuwahara F; Katayama E; Nakama T
    J Dermatolog Treat; 2019 Jun; 30(4):383-386. PubMed ID: 30221571
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
    Ighani A; Georgakopoulos JR; Zhou LL; Walsh S; Shear N; Yeung J
    J Cutan Med Surg; 2018; 22(3):290-296. PubMed ID: 29373924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug survival of apremilast in patients treated for psoriasis in a real-world setting.
    Lee EB; Amin M; Wu JJ
    J Am Acad Dermatol; 2018 Oct; 79(4):760-761. PubMed ID: 29588246
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug survival of apremilast in a real-world setting.
    Kishimoto M; Komine M; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2019 Jul; 46(7):615-617. PubMed ID: 31180150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
    Armstrong A; Levi E
    J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis.
    Phan C; Beneton N; Delaunay J; Reguiai Z; Boulard C; Fougerousse AC; Cinotti E; Romanelli M; Mery-Bossard L; Thomas-Beaulieu D; Parier J; Maccari F; Chaby G; Bastien M; Begon E; Samimi M; Prignano F; Beauchet A; Mahé E;
    Drugs Aging; 2020 Sep; 37(9):657-663. PubMed ID: 32696432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
    Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
    J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study.
    Ighani A; Georgakopoulos JR; Shear NH; Walsh S; Yeung J
    J Am Acad Dermatol; 2018 Apr; 78(4):801-803. PubMed ID: 29017843
    [No Abstract]   [Full Text] [Related]  

  • 12. Real-world use of apremilast for patients with psoriasis in Japan.
    Kishimoto M; Komine M; Hioki T; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2018 Nov; 45(11):1345-1348. PubMed ID: 30168880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.
    Wong TH; Sinclair S; Smith B; Fraser C; Morton CA
    Clin Exp Dermatol; 2017 Aug; 42(6):675-676. PubMed ID: 28621002
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors that may influence the choice for initiating apremilast or methotrexate treatment for psoriasis in real-world clinical setting.
    Fougerousse AC; Maccari F; Beauchet A; Parier J; Boulard C; Becherel PA; Quiles-Tsimaratos N; Le Guyadec T; Thomas-Beaulieu D; Halioua B; Begon E; Bastien M; Perrot JL; Pallure V; Bilan P; Steff M; Pfister P; Vermersch-Langlin A; Boyé T; Mery-Bossard L; Maillard H; Kemula M; Girard C; Poiraud C; Monfort JB; Kupfer-Bessaguet I; Perrussel M; Lons-Danic D; Sultan N; Lorier E; Zeitoun M; Wagner L; Gabison G; Mahé E;
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):e476-e478. PubMed ID: 31310364
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world data on the efficacy and safety of apremilast in patients with moderate-to-severe plaque psoriasis.
    Papadavid E; Rompoti N; Theodoropoulos K; Kokkalis G; Rigopoulos D
    J Eur Acad Dermatol Venereol; 2018 Jul; 32(7):1173-1179. PubMed ID: 29388335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
    Knuckles MLF; Levi E; Soung J
    J Dermatolog Treat; 2019 Aug; 30(5):430-434. PubMed ID: 30339049
    [No Abstract]   [Full Text] [Related]  

  • 17. Apremilast in psoriasis - a prospective real-world study.
    Vujic I; Herman R; Sanlorenzo M; Posch C; Monshi B; Rappersberger K; Richter L
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):254-259. PubMed ID: 28925560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study.
    Ighani A; Georgakopoulos JR; Walsh S; Shear NH; Yeung J
    J Am Acad Dermatol; 2018 Mar; 78(3):623-626. PubMed ID: 28989112
    [No Abstract]   [Full Text] [Related]  

  • 19. Maintenance of therapeutic response after 1 year of apremilast combination therapy compared with monotherapy for the treatment of plaque psoriasis: A multicenter, retrospective study.
    Ighani A; Georgakopoulos JR; Shear NH; Walsh S; Yeung J
    J Am Acad Dermatol; 2018 Nov; 79(5):953-956. PubMed ID: 29730366
    [No Abstract]   [Full Text] [Related]  

  • 20. Adverse events associated with apremilast use and withdrawal for psoriasis in a real-world setting.
    Lee EB; Amin M; Egeberg A; Wu JJ
    J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):e393-e394. PubMed ID: 29730885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.